ReviewFrontiers in pharmacology2021

Absence of Biomarker-Driven Treatment Options in Small Cell Lung Cancer, and Selected Preclinical Candidates for Next Generation Combination Therapies.

Nicholas R Liguori et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.